16.	Subsequent Events

On February 13, 2018, the Company entered into an underwriting agreement with JonesTrading, in connection with a registered firm commitment underwritten public offering of 2,941,176 shares of common stock, pursuant to a shelf registration statement that was declared effective by the SEC on February 6, 2018. On February 15, 2018 the Company sold 3,382,352 shares of common stock (including 441,176 shares of common stock sold pursuant to the exercise of the underwriters’ overallotment option) at a price to the public of $34.00 per share. The net proceeds to the Company, after deducting the underwriting discounts and commissions and offering expenses payable by the Company were approximately $106.7 million.

On February 19, 2018, the Redeemable Convertible notes matured and the remaining Notes were repaid in full with cash from the restricted cash indenture. The Company has no outstanding Notes remaining as of February 20, 2018.

On February 21, 2018, the Company and AGC Biologics (“AGC”), formerly known as CMC ICOS Biologics, Inc. entered into a new statement of work under the development and manufacturing services agreement dated May 20, 2016, between the Company and AGC. Under the new statement of work, the Company has engaged AGC for the process transfer and commercial scale cGMP manufacturing of CB 2679d, Catalyst’s highly potent next-generation coagulation FIX variant being developed for the treatment of severe hemophilia B. The Company has agreed to a total of approximately $5.6 million in payments pursuant to the new statement of work, including the commercial scale manufacturing of CB 2679d, subject to completion of applicable work stages.

On March 2, 2018, the Company called all 3,580 outstanding shares of Series A Preferred Stock to be converted into common stock effective as of March 7, 2018. As of March 15, 2018, the Series A Preferred Stock was converted into 716,000 shares of common stock and there were no Series A Preferred Stock outstanding.

On March 5, 2018, the Company called the remaining 254,628 outstanding warrants. As of March 15, 2018, there were 45,628 warrants remaining and approximately $9.3 million proceeds received from warrants exercised during 2018. Warrant holders have until 6:30PM EST on March 19, 2018 to exercise their warrants, after this date the remaining outstanding warrants will be cancelled and the right to exercise such warrants will extinguish.